Metsera’s long-acting GLP-1 looks competitive in Phase 2 obesity study
Data from a mid-stage obesity trial of Metsera’s long-acting injectable GLP-1 agonist suggest it could be competitive with approved incretins and several investigational compounds. The Phase 2a trial...
View ArticleNovo Nordisk partners with Variant Bio; Aviceda raises $207M in Series C
Plus, news about Alebund Pharmaceuticals, Capsida Biotherapeutics, CytomX Therapeutics and Generation Bio: Novo Nordisk’s latest obesity partner: The Danish pharma giant is teaming up with a small...
View ArticlePfizer extends AI drug discovery pact with PostEra, adding ADCs to deal
Pfizer has re-upped its drug discovery deal with AI startup PostEra to develop small molecule drugs and new warheads for antibody-drug conjugates, a major area of focus for the drugmaker following its...
View ArticleImmuneering touts positive pancreatic cancer data for MEK inhibitor
Immuneering’s shares rocketed in premarket trading on Tuesday on the back of positive mid-stage data for its MEK inhibitor in pancreatic cancer, sparking plans to add more combination arms. Three out...
View ArticleCompounding pharmacies face an uphill battle in fight over tirzepatide
Eli Lilly has officially waded into a legal battle between a trade group for large compounding facilities, a small compounding pharmacy and the FDA, after a Texas federal court granted ...
View ArticleBWX Technologies to buy Canadian isotope maker for $525M
This year's first radiopharmaceutical deal is slated to expand BWX Technologies’ presence in the North American nuclear tech market as demand is expected to creep up. Virginia-headquartered BWX...
View ArticleCalico, Denali's ALS drugs miss primary objectives in basket study
A basket study for experimental ALS treatments recorded a pair of additional failures on Monday from two prominent companies. New data from Google’s longevity play Calico and the neuro-focused biotech...
View ArticleDrugmakers cut list prices for some cancer, asthma and diabetes treatments
Bayer’s Nexavar and Boehringer Ingelheim's Spiriva are among a handful of drugs with reduced US list prices for the new year, according to a Tuesday analysis that showed average prices growing ...
View ArticleFDA sets an efficacy threshold for new weight loss drugs
New anti-obesity drugs should meet a minimum level of weight loss to be considered for approval, the FDA said Tuesday, taking the rare step of proposing an efficacy threshold for future products. In a...
View ArticleAetna takes Takeda to court over 'anticompetitive scheme' with generic drugs
Aetna is going after another pharmaceutical company for alleged price fixing. The health insurance provider filed suit against Takeda on Friday over what it says was an “anticompetitive scheme” to keep...
View ArticleNumber of FDA product adcomms last year returned to 2022 levels
The FDA held 13 advisory committee panels last year to discuss specific product applications, half the total in 2023 and compared with nine in 2022. The review by Endpoints News included all advisory...
View ArticleSanofi partners with Alloy Therapeutics to make new CNS drug
Sanofi has enlisted drug discovery company Alloy Therapeutics to develop an antisense oligonucleotide drug for a single, undisclosed central nervous system target. Sanofi will pay Alloy up to $27.5...
View ArticleMaze files for first biotech IPO of 2025, following $115M funding boost
Maze Therapeutics has submitted its pitch for an initial public offering after disclosing a $115 million Series D, forging a neuroscience spinoff and running into a dealmaking hurdle ...
View ArticleNovo expands pact with Flagship's Valo to include obesity, diabetes for $190M...
Novo Nordisk is doubling down on its computational biotech partner Valo Health, expanding their collaboration from 11 potential drugs to 20. Wednesday morning's extended pact with the Flagship-founded...
View ArticleJasper reports more data in spontaneous hives from tiny study
Jasper Therapeutics continued building out the data for a drug designed to treat irritable skin conditions, though the latest results came from a small trial and without p-values. Researchers tested...
View ArticleLB Pharmaceuticals reveals Phase 2 schizophrenia data
A private startup looking to bring an old schizophrenia drug class to the US has released new Phase 2 data and aims to start a pivotal trial this year. On Wednesday, LB Pharmaceuticals said its ...
View ArticleUpdated: Galapagos to split into two companies, slash headcount as it eyes...
Galapagos is looking to have a fresh start after a rough few years. The Belgian biotech has outlined plans to branch off into two publicly traded businesses in a move that will see it terminate ...
View ArticleVir’s early T cell engager data offer first look at cancer pivot, stock jumps
Interim data on two T cell engagers that Vir Biotechnology licensed from Sanofi last year have begun to justify the biotech’s strategic shift into oncology. But the data are very early, and ...
View ArticleExclusive: GV-backed Prudentia launches with $7M to boost pharma dealmaking
Ahead of the busiest week for biopharma dealmaking at the annual JP Morgan Healthcare Conference, a new startup launched, believing its software will help prevent drugmakers from missing out on their...
View ArticleNovo-allied Aspect Biosystems nabs $115M for bioprinted tissue therapies
A Canadian biotech creating bioprinted tissue therapeutics for Type 1 diabetes, obesity and other endocrine and metabolic disorders has raised $115 million in a Series B. Vancouver-based Aspect...
View Article